Free Trial
NASDAQ:PTIX

Atrinsic 4/1/2024 Earnings Report

Atrinsic logo
$2.75 -0.05 (-1.79%)
Closing price 08/12/2025 04:00 PM Eastern
Extended Trading
$2.74 -0.01 (-0.33%)
As of 08/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atrinsic EPS Results

Actual EPS
-$5.32
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
Protagenic Therapeutics swaps warrants for shares
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile

More Earnings Resources from MarketBeat